var data={"title":"Xylometazoline (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Xylometazoline (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7166?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=xylometazoline-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Xylometazoline (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234973\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Balminil Decongest [OTC];</li>\n      <li>Otrivin [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235001\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Alpha-Adrenergic Agonist;</li>\n      <li>\n        Decongestant;</li>\n      <li>\n        Imidazoline Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234974\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Nasal congestion:</b> Intranasal:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Drops (0.1%): Apply 2 to 3 drops in each nostril every 8 to 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metered dose spray (0.1%):  1 spray in each nostril every 8 to 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Spray (0.05%, 0.1%):  1 or 2 sprays in each nostril every 8 to 10 hours </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234975\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46106896\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution, Nasal, as hydrochloride [drops]: 0.1%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution, Nasal, as hydrochloride [metered dose spray]: 0.1%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution, Nasal, as hydrochloride [spray]: 0.05%, 0.1%</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46106895\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46106891\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For intranasal use only. Blow nose to clear nostrils before use. Tilt head slightly forward (for spray) or backward (for drops) and then spray solution or apply drops into each nostril. After application of spray or drops inhale deeply. Wipe tip of container clean after each use. Some products may need to be primed prior to initial use (refer to package labeling).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234965\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Nasal Congestion:</b> Temporary relief of nasal and nasopharyngeal mucosal congestion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F235005\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Sound-alike/look-alike issues: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Otrivin may be confused with Lotrimin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234959\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Application site burning</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Dry nose, nasal discomfort</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Cardiac arrhythmia, hypersensitivity reaction, tachycardia, visual impairment (transient)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46106201\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to xylometazoline or any component of the formulation; patients with transphenoidal hypophysectomy or surgery exposing the dura mater; narrow angle glaucoma; rhinitis sicca or atrophic rhinitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46106227\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Rebound nasal congestion: Frequent or prolonged use may cause nasal congestion to recur or worsen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with hypertension or heart disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes mellitus: Use with caution in patients with diabetes mellitus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thyroid disease: Use with caution in patients with thyroid disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Prostatic hyperplasia/Urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: If symptoms persist longer than 3 days consult health care provider. Container should not be used by more than 1 individual.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300230\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234960\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=106757&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.<b> Exceptions: </b>Ergoloid Mesylates; Nicergoline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details.<b> Exceptions: </b>Linezolid; Tedizolid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the vasopressor effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46106195\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">According to the manufacturer, use during pregnancy is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46106198\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if xylometazoline is excreted in breast milk. The manufacturer recommends that caution be exercised when administering xylometazoline to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234956\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stimulates alpha-adrenergic receptors in the arterioles of the conjunctiva and the nasal mucosa to produce vasoconstriction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234967\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Intranasal: Local vasoconstriction: Within 2 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Up to 12 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46251933\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Triaminic Nasal &amp; Sinus Cong Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (20 mL): $4.85</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>The pricing data provide a representative AWP and/or AAWP price from a single manufacturer of the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for reimbursement or purchasing functions. Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234968\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Af-Care (IL);</li>\n      <li>Amidrin (ES);</li>\n      <li>Antazol (BD);</li>\n      <li>Balkis (DE, LU);</li>\n      <li>Cirovin (LK);</li>\n      <li>Colirio Azul (CO);</li>\n      <li>Decon (LK);</li>\n      <li>Decozal (ET);</li>\n      <li>Ezybreth (LK);</li>\n      <li>Fastorik N (TZ);</li>\n      <li>FLO Xylo-POS Nasal Spray (AU);</li>\n      <li>Galazolin (LV);</li>\n      <li>Gelonasal (DE);</li>\n      <li>Halazolin (UA);</li>\n      <li>Hidropid (HR);</li>\n      <li>Huma-Metazol (HU);</li>\n      <li>Hysan (MT);</li>\n      <li>Nasan (HU, LU);</li>\n      <li>NasenGel ratiopharm (LU);</li>\n      <li>NasenSpray ratiopharm (LU);</li>\n      <li>NasenTropfen ratiopharm (LU);</li>\n      <li>Nasoferm (SE);</li>\n      <li>Nasolin (FI);</li>\n      <li>Nazol N (HR);</li>\n      <li>Neusdruppels (NL);</li>\n      <li>Novin (BD);</li>\n      <li>Novorin (HU);</li>\n      <li>Olynth (CH, EE, HR, LV, RU);</li>\n      <li>Otrinase (RO);</li>\n      <li>Otriven (DE);</li>\n      <li>Otrivin (AE, AT, BG, CH, CY, CZ, DK, EE, EG, ES, ET, FI, GR, HK, HN, HU, ID, IL, IN, IS, IT, JO, KR, KW, LB, LT, LV, MT, MY, NL, NO, NZ, PH, PL, QA, SA, SE, SG, SI, SK, TH, TW, VN, ZW);</li>\n      <li>Otrivina (AR, BR, PY, UY);</li>\n      <li>Otrivine (BE, GB, IE, LU, TR);</li>\n      <li>Otryvin (UA);</li>\n      <li>Pen Ke Tong (TW);</li>\n      <li>Rhinidine (LU);</li>\n      <li>Rhinozol (BD);</li>\n      <li>Senziola (IE);</li>\n      <li>Sinuvin (BD);</li>\n      <li>Snup Stada (HK);</li>\n      <li>Tezoline (RO);</li>\n      <li>Tyzin (UA);</li>\n      <li>Xoline (PK);</li>\n      <li>Xylo-POS (IL);</li>\n      <li>Xylolin (AE, KW, QA, SA);</li>\n      <li>Xylomet (AE, BH, KW, QA, SA);</li>\n      <li>Xylovit (IL);</li>\n      <li>Xymelin (LV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Otrivin (xylometazoline). Mississauga, Ontario, Canada: Novartis Consumer Health Canada Inc. Available at: http://www.otrivin.ca/en/index.shtml. Accessed 1/20/2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Otrivin (xylometazoline) [product monograph]. Mississauga, Ontario, Canada: Novartis Consumer Health Canada Inc; January 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 106757 Version 21.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F234973\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F235001\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F234974\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F234975\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F46106896\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F46106895\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F46106891\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F234965\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F235005\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F234959\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F46106201\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F46106227\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300230\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F234960\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F46106195\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F46106198\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F234956\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F234967\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F46251933\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F234968\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/106757|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=xylometazoline-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Xylometazoline (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}